drugset / Trial / NCT07081256

To Evaluate the Efficacy and Safety of QLM2010 for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

NCT07081256 ↗

Phase 3 Completed 665 enrolled Qilu Pharmaceutical Co., Ltd.
RandomizedParallel-groupQuadruple-blindPrevention

Summary

Compared With Fosaprepitant dimeglumine for Injection and Palonosetron Hydrochloride Injection, to Evaluate the Efficacy and Safety of QLM2010 for Injection for Prevention of Chemotherapy-induced Nausea and Vomiting After Highly Emetogenic Chemotherapy.

Timeline

Start
2025-01-03
Primary completion
2025-08-25
Completion
2025-10-15

Drugs

EvaluationDrugModalityDoseRoute
Comparator Palonosetron Other / unclassified — —
Subject QLM2010 Unknown — —
Comparator fosaprepitant dimeglumine Unknown — —
Background Dexamethasone Small molecule — —